Abstract 154P
Background
Casdozo is the first in class and only clinical-stage IL-27 targeting antibody, which inhibits IL-27 signaling and T and NK cell immune inhibition leading to increased IFN-γ and NK cell gene activation in patients (pts) with cancer. A phase 1 dose-escalation and dose-expansion study of casdozo in advanced solid tumors demonstrated favorable safety and reversal of IL-27-mediated immune suppression. We present updated antitumor activity, safety, and biomarker data of casdozo monotherapy in pts with NSCLC.
Methods
A phase 1 dose-escalation and dose-expansion study explored casdozo monotherapy 10 mg/kg IV q4 wks in treatment-refractory NSCLC.
Results
As of August 27, 2024, 45 pts with NSCLC received casdozo (5 dose-escalation; 40 dose-expansion); median time on treatment was 8 wks; median follow-up time on study was 9 wks. Most had adenocarcinoma (73%) or squamous (25%) histology. The majority received casdozo as ≥3rd line (67%). Treatment-related adverse events (TRAEs) occurred in 18 (40%) of pts and were primarily grade 1/2 (fatigue was the most common, n=4 [9%]). Of the 43 response-evaluable pts, 2 partial responses were seen in anti-PD-(L)1-experienced pts with squamous histology, resulting in a 22% ORR in squamous NSCLC (2/9 pts). Immunohistochemistry of a responder’s archival squamous tumor showed an immune excluded phenotype by CD8 staining and presence of IL-27-expressing tumor associated macrophages (TAMs). Cytokine profiling of pt serum samples revealed a casdozo-induced increase in IFN-γ. Bulk RNAseq analysis of paired PBMC samples showed casdozo inhibited IL-27 signaling and activated NK and T cell signatures.
Conclusions
Casdozo, the only clinical-stage IL-27 antagonistic antibody, is well-tolerated as monotherapy and demonstrated antitumor activity in heavily pretreated, anti-PD-(L)1-experienced pts with squamous NSCLC. Biomarker data confirmed casdozo-mediated pharmacodynamic activity and immune activation. These findings support further evaluation of casdozo in pts with PD-1 experienced squamous NSCLC; a phase 1b study of casdozo with the anti-PD-1 inhibitor toripalimab is ongoing.
Clinical trial identification
NCT04374877.
Editorial acknowledgement
Olivia Adams The Phillips Group Oncology Communications, Inc.
Legal entity responsible for the study
Coherus BioSciences.
Funding
Coherus BioSciences.
Disclosure
A. Naing: Financial Interests, Personal, Speaker, Consultant, Advisor: CTI, Deka Biosciences, Janssen Biotech, Mural Oncology, NGM Bio, PsiOxus Therapeutics, Immune-Onc Therapeutics, STCube Pharmaceuticals, OncoSec KEYNOTE-695, Genome & Company, CytomX Therapeutics, Nouscom, Merck Sharp & Dohme, Servier, Lynx Health, AbbVie; Financial Interests, Personal, Speaker’s Bureau: AKH Inc., The Lynx Group, Society for Immunotherapy of Cancer (SITC), Korean Society of Medical Oncology (KSMO), Scripps Cancer Care Symposium, ASCO Direct Oncology Highlights, European Society for Medical Oncology (ESMO), CME Outfitters; Financial Interests, Personal, Other: ARMO BioSciences, NeoImmuneTech, NGM Biopharmaceuticals, NCI, EMD Serono, MedImmune, Healios Onc Nutrition, Atterocor/Millendo, Amplimmune, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer, CytomX, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab PsiOxus, Arcus Biosciences, NeoImmuneTech, Immune-Onc Therapeutics, Surface Oncology, Monopteros Therapeutics, BioNTech SE, Seven & Eight Biopharma, SOTIO Biotech AG, GV20 Therapeutics. C. Mantia: Financial Interests, Institutional, Research Funding: Bristol Myers Squibb; Financial Interests, Personal, Speaker, Consultant, Advisor: Nextech, Cogent Biosciences; Financial Interests, Personal, Advisory Board: Synthekine. N. Pennell: Financial Interests, Personal, Speaker, Consultant, Advisor: Sanofi Genzyme, Bayer, Summit Therapeutics, Nuvation Bio, Genentech, BMS, Takeda, Johnson and Johnson, Eli Lilly; Financial Interests, Personal, Advisory Board: Iovance, Daiichi Sankyo. H.R. Kim: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Bristol Myers Squibb, Genentech/Roche; Financial Interests, Personal, Stocks or ownership: BridgeBio Therapeutics. L. Villaruz: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Johnson and Johnson, EMD Serono, Sanofi, Gilead, Daiichi Sankyo, Takeda, Jazz Pharmaceuticals. A.B. El-Khoueiry: Financial Interests, Personal, Advisory Board: Exelixis, AstraZeneca, Genentech, Agenus, Tallac, ABL Bio, Senti Biosciences, Qurient; Financial Interests, Institutional, Funding: Fulgent, Astex, AstraZeneca; Financial Interests, Personal, Steering Committee Member: Merck, Genentech; Financial Interests, Personal, Coordinating PI: Genentech; Financial Interests, Institutional, Coordinating PI, trial; funding: Auransa; Non-Financial Interests, Personal, Principal Investigator: Agenus, Affimed, Bayer. D.E. Gerber: Financial Interests, Institutional, Research Grant: AstraZeneca, BerGenBio, Karyopharm, Novocure; Financial Interests, Personal, Royalties: Oxford University Press; Financial Interests, Personal, Speaker, Consultant, Advisor: Catalyst Pharmaceuticals; Financial Interests, Personal, Other, US Patent 11,747,345; U.S. patent applications 17/045,482, 63/386,387, 63/382,972, 63/382,257; US Patent; Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, Daiichi Sankyo, Elevation Oncology, Janssen Scientific Affairs, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi; Financial Interests, Personal, Leadership Role: OncoSeer Diagnostics, Inc. A. Qin: Financial Interests, Institutional, Research Grant: Genentech, AstraZeneca, Merck, Johnson and Johnson; Financial Interests, Personal, Speaker, Consultant, Advisor: Genentech, Pfizer, Johnson and Johnson, Regeneron, Summit Therapeutics, Strata Oncology; Financial Interests, Personal, Speaker’s Bureau: OncLive, MSHO, Medscape, Binaytara Foundation, Dava Oncology. M. Altan: Financial Interests, Personal, Advisory Board: GSK, Bristol Myers Squibb, Shattuck Lab, AstraZeneca, Insightec; Financial Interests, Personal, Invited Speaker: Nektar Therapeutics; Financial Interests, Personal, Other, Participation of independent data safety committee: Henlius; Financial Interests, Institutional, Other, Participation of Safety review committee for Nanobiotix-MDA Alliance: Nanobiotics; Financial Interests, Institutional, Local PI: Genentech, Nektar Therapeutics, Merck, GSK, Jounce Therapeutics, Bristol Myers Squibb, Shattuck Lab, Gilead, Verismo Therapeutics, Lyell. H. Tang, K. Iizuka, V. Kapoor, D. Chin: Financial Interests, Personal, Full or part-time Employment: Coherus BioSciences. T. Marron: Financial Interests, Personal, Advisory Board: Regeneron, AstraZeneca, Genentech, G1 Therapeutics, Arcus, Glenmark, Merck, NGMBio, Glenmark, AbbVie, Fate; Financial Interests, Institutional, Coordinating PI: Regeneron, Genentech, Boehringer Ingelheim, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract